Dyspareunia News and Research

RSS

Warning over exposure risk with TVT-Secur mini-sling

The TVT-Secur mini-sling is associated with a higher risk of prosthesis exposure than another mini-sling from the same manufacturer, shows a large study by French researchers.

6 May 2014

Study evaluates mesh-related complications for surgical management of female POP

Younger age, less prominent prolapse and concomitant hysterectomies are associated with a higher risk of peri-operative and mesh-related complications after prolapse repair with trocar-guided transvaginal mesh, according to a study presented by a Russian group at the 28th Annual EAU Congress.

21 Mar 2013

Shionogi receives FDA approval for Osphena to treat women with severe dyspareunia

The U.S. Food and Drug Administration today approved Osphena (ospemifene) to treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.

26 Feb 2013

Positive results from Palatin’s bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

9 Nov 2012

Ventral rectoplexy helps recover sexual function

Laparoscopic ventral rectoplexy may reduce sexual dysfunction in women with complex posterior floor prolapse, say researchers who found many patients appreciated having postoperative investigation of their symptoms.

13 Jun 2012

Neurocrine announces results from elagolix Phase II Daisy PETAL study in endometriosis

Neurocrine Biosciences, Inc. today announced results from the open-label portion of the six month Phase II Daisy PETAL study (901 study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

22 Nov 2010

Meditrina licensor AstraZeneca granted US allowance of patent for endometriosis treatment

Meditrina Pharmaceuticals, Inc., a clinical-stage, specialty pharmaceutical company focused on developing and commercializing innovative therapies that treat women's reproductive system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Composition Comprising a Combination of an Aromatase Inhibitor, a Progestin, and an Oestrogen and its Use for the Treatment of Endometriosis" to the Company's licensor AstraZeneca.

10 Sep 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

Quatrx' second phase 3 study of ospemifene tablets provides positive results

QuatRx Pharmaceuticals Company, a privately-held biopharmaceutical company, today announced positive efficacy results from the second of two patient cohorts in the second pivotal Phase 3 study for Ophena(TM) (ospemifene tablets), the company's investigational compound in development for the treatment of postmenopausal vulvovaginal atrophy (VVA).

10 Sep 2009

LUNA surgical procedure did not alleviate chronic pelvic pain in women

A surgical procedure known as LUNA (laparoscopic uterosacral nerve ablation) did not result in improvements in chronic pelvic pain, painful menstruation, painful sexual intercourse or quality of life when compared with laparoscopic surgery that does not interrupt pelvic nerve connections, according to a study in the September 2 issue of JAMA.

2 Sep 2009

Women warned about cosmetic vaginal surgery

The American College of Obstetricians and Gynecologists (ACOG) has warned women against cosmetic procedures advertised as "vaginal rejuvenation," "designer vaginoplasty", "revirgination" and "G-spot amplification".

3 Sep 2007

Prevalence of Peyronie's disease in men with erectile dysfunction

Peyronie's disease (PD) is a localized connective tissue disorder that primarily affects the tunica albuginea and the areolar space between the tunica albuginea and erectile tissue.

17 Apr 2006

Intravaginal surface electromyography (SEMG) being used to treat vaginal pain

The diagnosis and treatment of vulvovaginal pain disorders are progressing through the advancement of intravaginal surface electromyography (SEMG).

27 Mar 2006

Interventional radiologists now are able to treat using minimally invasive procedures

Interventional radiologists at Temple University Hospital now are able to treat many patients with minimally invasive procedures not available only a few years ago. “Conditions that used to require extensive surgery now take an hour or less, and patients leave with a bandaid and walk home,” says Gary Cohen, M.D., Section Chief of Interventional Radiology and Vice Chairman of Radiology. “How can you beat that?”

17 May 2004